Chiara Della Pepa

Dr. Chiara Della Pepa

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
Massimiliano BerrettaMassimiliano Berretta
Massimiliano Berretta
CPChiara Della Pepa
Chiara Della Pepa
PTPaolo Tralongo
Paolo Tralongo
AFAlberto Fulvi
Alberto Fulvi
FMFerdinando Martellotta
Ferdinando Martellotta
GFGAETANO FACCHINI
GAETANO FACCHINI
Use of Complementary and Alternative Medicine (CAM) in cancer patients: An Italian multicenter survey


20 September 2010 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
SDSantini Daniele
Santini Daniele
Giuseppe PerroneGiuseppe Perrone
Giuseppe Perrone
IRIlaria Roato
Ilaria Roato
LGLaura Godio
Laura Godio
FPFrancesco Pantano
Francesco Pantano
GTGiuseppe Tonini
Giuseppe Tonini

5 January 2015 in Chinese Journal of Cancer
Verified
Journal Article
Open access
CPChiara Della Pepa
Chiara Della Pepa
GTGiuseppe Tonini
Giuseppe Tonini
CPCarmela Pisano
Carmela Pisano
MNMarilena Di Napoli
Marilena Di Napoli
SCSabrina Chiara Cecere
Sabrina Chiara Cecere
SPSandro Pignata
Sandro Pignata
Ovarian cancer remains a major issue for gynecological oncologists, and most patients are diagnosed when the disease is already advanced with a poor chance of survival. Debulking surgery followed by platinum-taxane chemotherapy is the current standard of care, but based on several different strategies currently under evaluation, some encouraging data have been published in the last 4 to 5 years. This review provides a state-of-the-art overview of the available alternatives to conventional treatment and the most promising new combinations. For example, neoadjuvant chemotherapy does not seem to be inferior to primary debulking. Despite its outcome improvements, intraperitoneal chemotherapy struggles for acceptance due to the heavy toxicity. Dose-dense chemotherapy, after showing an impressive efficacy in Asian populations, has not produced equal results in a European cohort, and the results of alternative platinum doublets are not superior to those of carboplatin and paclitaxel. In this setting, adherence to a maintenance therapy after first-line treatment and multiple (primarily antiangiogenic) agents appears to be effective. Although many questions, including the duration of maintenance treatment and the use of bevacizumab beyond progression, remain unanswered, new biologic agents, such as poly(ADP-ribose) polymerase (PARP) inhibitors, nintedanib, and mitogen-activated protein/extracellular signal-regulated kinase (MEK) inhibitors, have emerged as potential therapeutic options in the very near future. Based on the multiplicity of available strategies, the histological and molecular features of the tumor, in addition to patient's clinical condition and disease state, continue to gain importance in guiding treatment choices.

1 February 2015 in Cancer Treatment Reviews
Verified
Journal Article
Closed access
CPChiara Della Pepa
Chiara Della Pepa
GTGiuseppe Tonini
Giuseppe Tonini
SDSantini Daniele
Santini Daniele
SLSimona Losito
Simona Losito
CPCarmela Pisano
Carmela Pisano
SPSandro Pignata
Sandro Pignata

30 June 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AGAngela George
Angela George
JMJennifer McLachlan
Jennifer McLachlan
NTNina Tunariu
Nina Tunariu
CPChiara Della Pepa
Chiara Della Pepa
CMCristina Migali
Cristina Migali
SBSusana Banerjee
Susana Banerjee
Hormonal therapy is used as a treatment option in high-grade ovarian carcinoma (HGOC), but the role and choice of treatment remains unclear. Agents used include tamoxifen and aromatase inhibitors. Our aim was to evaluate the efficacy of tamoxifen (T) and letrozole (L) in HGOC in clinical practice and investigate factors influencing clinical outcome. A retrospective review of patients with relapsed HGOC treated with either tamoxifen or letrozole at the Royal Marsden Hospital between 2007 and 2012 was performed. The primary endpoint of the study was objective response rate (ORR). Secondary endpoints included CA125 response, clinical benefit rate (CBR) and duration of response. Platinum-sensitivity and ER-status were evaluated as predictors of treatment response. 97 patients were included (43 T, 54 L); median age 63 years (20–92); 91% high-grade serous; median number of lines of prior chemotherapy 3 (1–8); 60% platinum-resistant, 40% platinum-sensitive; 52% ER + ve, 1% ER-ve, 47% unknown. 14 patients (6 T, 8 L) achieved a partial response, with ORR (RECIST) of 14% (T) and 15% (L). The CBR for ≥3 months was 65% (22/43) for tamoxifen and 56% (22/54) for letrozole. There was no significant difference in ORR (p = 0.99) or CBR (p = 0.14) between tamoxifen and letrozole. 22 patients (23%) had a CA-125 response with hormonal therapy (10 T – 23% and 12 L – 22%). ORR did not differ by platinum sensitivity (p = 0.42); or ER-status (positive vs unknown, p = 0.12). Responders to letrozole had longer durations of response than responders to tamoxifen (26 vs 11.5 months, p = 0.03), but equivalent disease stability duration (9.6 vs 7.2 months respectively, p = 0.11). Within the constraints of a retrospective study, we identified that patients treated with letrozole had a significantly longer duration of response than those treated with tamoxifen. Treatment with either tamoxifen or letrozole is a rational treatment option for patients with ER + ve HGOC, with equivalent ORR, CBR and disease stability.